The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients
Open accessAbstract
Intravenous ganciclovir is the standard treatment for cytomegalovirus disease in solid organ transplant recipients. Oral valganciclovir is a more convenient alternative. In a randomized, international trial, recipients with cytomegalovirus disease were treated with either 900 mg oral valganciclovir or 5 mg/kg i.v. ganciclovir twice daily for 21 days, followed by 900 mg daily valganciclovir for 28 days. A total of 321 patients were evaluated (valganciclovir [n = 164]; i.v. ganciclovir [n = 157]). The success rate of viremia eradication at Day 21 was 45.1% for valganciclovir and 48.4% for ganciclovir (95% CI -14.0% to +8.0%), and at Day 49; 67.1% and 70.1%, respectively (p = NS). Treatment success, as assessed by investigators, was 77.4% versus 80.3% at Day 21 and 85.4% versus 84.1% at Day 49 (p = NS). Baseline viral loads were not different between groups and decreased exponentially with similar half-lives and median time to eradication (21 vs. 19 days, p = 0.076). Side-effects and discontinuations of assigned treatment (18 of 321 patients) were comparable. Oral valganciclovir shows comparable safety and is not inferior to i.v. ganciclovir for treatment of cytomegalovirus disease in organ transplant recipients and provides a simpler treatment strategy, but care should be taken in extrapolating to organ transplant recipients not properly represented in the present study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infection in Organ-Transplant Recipients
Fishman, J. A., & Rubin, R. H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806113382407 · Cited by 1,622
Paya, C., Humar, A., Dominguez, E., Washburn, K., Blumberg, E., Alexander, B., Freeman, R., Heaton, N., & Pescovitz, M. D. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00382.x · Cited by 880
Self-citationHumar, A., & Michaels, M. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01207.x · Cited by 487
Self-citationA Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis
Martin, D. F., Sierra-Madero, J., Walmsley, S., Wolitz, R. A., Macey, K., Georgiou, P., Robinson, C. A., & Stempien, M. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011759 · Cited by 394
Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients
Pescovitz, M. D., Rabkin, J., Merion, R. M., Paya, C. V., Pirsch, J., Freeman, R. B., O'Grady, J., Robinson, C., To, Z., Wren, K., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2811-2815.2000 · Cited by 357
Self-citationCytomegalovirus (CMV) DNA Load Predicts Relapsing CMV Infection after Solid Organ Transplantation
Sia, I. G., Wilson, J. A., Groettum, C. M., Espy, M. J., Smith, T. F., & Paya, C. V. (2000) · The Journal of Infectious Diseases · doi:10.1086/315242 · Cited by 220
Gerna, G., Lilleri, D., Fornara, C., Comolli, G., Lozza, L., Campana, C., Pellegrini, C., Meloni, F., & Rampino, T. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01488.x · Cited by 182
Human embryonic stem cells: A potential source for cellular therapy
Gerecht, S., & Itskovitz‐Eldor, J. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6135.2004.0345.x · Cited by 140
Caliendo, A. M., George, K. S., Kao, S.-Y., et al. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.6.2122-2127.2000 · Cited by 135
The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection
Scalzo, A. A., Corbett, A. J., Rawlinson, W. D., Scott, G. M., & Degli‐Esposti, M. A. (2006) · Immunology and Cell Biology · doi:10.1038/sj.icb.7100013 · Cited by 113
Cited by
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients
Eckardt, K.-U., Kasiske, B. L., & Zeier, M. G. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02834.x · Cited by 1,499
Kotton, C. N., Kumar, D., Caliendo, A. M., Huprikar, S., Chou, S., Danziger-Isakov, L., & Humar, A. (2018) · Transplantation · doi:10.1097/tp.0000000000002191 · Cited by 1,152
Self-citationKotton, C. N., Kumar, D., Caliendo, A. M., Åsberg, A., Chou, S., Snydman, D. R., Allen, U., & Humar, A. (2010) · Transplantation · doi:10.1097/tp.0b013e3181cee42f · Cited by 965
Self-citationKotton, C. N., Kumar, D., Caliendo, A. M., Åsberg, A., Chou, S., Danziger-Isakov, L., & Humar, A. (2013) · Transplantation · doi:10.1097/tp.0b013e31829df29d · Cited by 758
Self-citationRazonable, R. R., & Humar, A. (2019) · Clinical Transplantation · doi:10.1111/ctr.13512 · Cited by 753
Self-citation
Metadata
- Authors
- Asberg, A., Humar, A., Rollag, H., Jardine, A. G., Mouas, H., Pescovitz, M. D., Sgarabotto, D., Tuncer, M., Noronha, I. L., & Hartmann, A.
- Venue
- American Journal of Transplantation
- Publisher
- Elsevier BV
- Published
- 2007-09
- Volume
- 7
- Issue
- 9
- Pages
- 2106-2113
- ISSN
- 1600-6135 (ISSN-L)
- OpenAlex
- W2085476296
- Cited by
- 430
- References
- 13
- FWCI
- 17.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients. https://app.cochat.ai/papers/10.1111/j.1600-6143.2007.01910.x
- The paper
- Asberg, A., Humar, A., Rollag, H., Jardine, A. G., Mouas, H., Pescovitz, M. D., Sgarabotto, D., Tuncer, M., Noronha, I. L., & Hartmann, A. (2007). Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients. American Journal of Transplantation. https://doi.org/10.1111/j.1600-6143.2007.01910.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.